Home LiteratureArticle Details
PMID: 10430251 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma.

Cancer ·Vol. 86 ·No. 3 ·1999-08-01 ·Pages 429-38

Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N

Abstract

This report is an 8-year update of the authors' previous findings from National Surgical Adjuvant Breast Project (NSABP) Protocol B-17, which relates to the influence of pathologic characteristics on the natural history and treatment of intraductal carcinoma (DCIS). Nine pathologic features observed in a pathologic subset of 623 of 814 evaluable women enrolled in this randomized clinical trial were assessed for their role in the prediction of second ipsilateral breast tumors (IBT), other events, and selection of breast irradiation (XRT) following lumpectomy. The frequency of subsequent IBT was reduced from 31% to 13% (P = 0.0001) by XRT. The average annual hazard rates for IBT were reduced by XRT for all pathologic features examined. Four characteristics were individually noted to be significantly related to IBT, but only moderate-to-marked and absent-to-slight comedo necrosis were found to be independent high and low risk predictors, respectively, for such an event in patients of both treatment groups. XRT effected a 7% absolute reduction at 8 years in the low risk group. Despite a relatively high incidence (approximately 40%) of IBT consisting of invasive cancer, mortality due to breast carcinoma after DCIS for the entire cohort was found to be only 1.6% at 8 years. The degree of comedo necrosis in patients with DCIS appears to be sufficient for discriminating between high and low risks for IBT following lumpectomy for DCIS. Although margin status, unlike in our previous report, was found to have only a slight or borderline influence on the frequency of IBT at 8 years, excision of DCIS with free margins is advised. The low risk group exhibits a statistically significant reduction of IBT from XRT. The decision to forgo XRT in the treatment of this singular subset of patients would appear to depend on clinical considerations and the input of informed patients rather than being standard practice. [See editorial on pages 375-7, this issue.]

MeSH Terms
Breast Neoplasms/pathology,radiotherapy,surgery Carcinoma, Intraductal, Noninfiltrating/pathology,radiotherapy,surgery Cohort Studies Disease-Free Survival Female Follow-Up Studies Humans Mastectomy, Segmental Necrosis Neoplasm Invasiveness Neoplasm, Residual Neoplasms, Second Primary/pathology,prevention & control Proportional Hazards Models Prospective Studies
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Fisher E R
National Surgical Adjuvant Breast and Bowel Project Pathology Center, Pittsburgh, Pennsylvania, USA.
Dignam J
Tan-Chiu E
Costantino J
Fisher B
Paik S
Wolmark N
Article Info
Journal
Cancer
Abbr.
Cancer
ISSN
0008-543X
Published
1999-08-01
Pages
429-38
Language
English
Region
United States
NLM ID
0374236
Subset
IM
Grants
NCI NIH HHS · NCI-U10-CA-120270 · United States
NCI NIH HHS · NCI-U10-CA-37377 · United States
NCI NIH HHS · NCI-U10-CA-39086 · United States
Corrections
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com